$FB Recent News It’d be a ‘bad sign’ if Apple’s

New Post Public Reply Private Reply Replies (0) Message Board

Jan 3, 2015 at 10:41 AM

$FB Recent News

It’d be a ‘bad sign’ if Apple’s stock fell below this level 3:08 p.m. Jan. 2, 2015 - Jennifer Booton
Why growth-stock speculators need to be patient 1:46 p.m. Jan. 2, 2015 - The Trading Deck
Check your greed and Apple Watch at the door as we enter 2015 8:07 a.m. Jan. 2, 2015 - Barbara Kollmeyer
50 best companies to work for, according to employees 1:24 p.m. Jan. 1, 2015 - Catey Hill
Money-saving travel secrets from experts 12:01 p.m. Jan. 1, 2015 - MarketWatch
10 great stocks for 2015 from 3 market wizards 11:11 a.m. Jan. 1, 2015 - Michael Brush
Key sectors suggest further gains 2:00 p.m. Dec. 31, 2014 - The Trading Deck
Oil bottoms, stocks bubble, gold beckons 8:12 a.m. Dec. 31, 2014 - Shawn Langlois
Winklevoss Bitcoin Trust files to sell 20.1 million shares 7:51 a.m. Dec. 31, 2014 - Ciara Linnane
5 people getting rich off your New Year’s resolutions 7:17 a.m. Dec. 31, 2014 - Quentin Fottrell
8 technologies that will change the way you do everything 6:42 a.m. Dec. 31, 2014 - Jennifer Booton
Stock round-up 12:49 p.m. Dec. 30, 2014 - Cody Willard
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
This proves Apple is the stock retail investors love most 6:37 a.m. Dec. 30, 2014 - Anora Mahmudova
5 apps for spying on your spouse 8:27 a.m. Dec. 29, 2014 - Quentin Fottrell
The bubble that lurks in 2015 7:48 a.m. Dec. 29, 2014 - Shawn Langlois
Xiaomi raises another $1.1 billion to become most-valuable tech start-up 4:40 a.m. Dec. 29, 2014 - Douglas MacMillan
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
Will 2015 be Apple’s blue-chip debut? 1:31 p.m. Dec. 26, 2014 - Jennifer Booton
It might be a small-cap world after all in 2015 9:34 a.m. Dec. 26, 2014 - Barbara Kollmeyer

How to Fight the Campus Speech Police: Get a Good Lawyer 6:34 p.m. Jan. 2, 2015 - The Wall Street Journal Interactive Edition
Oracle's (ORCL) Cloud Portfolio Offers SMAC Solutions - Analyst Blog 5:45 p.m. Jan. 2, 2015 - Zacks.com
CES 2015: Wearables, Drones, Virtual-Reality Goggles 5:00 p.m. Jan. 2, 2015 - Investors Business Daily
Target's Analysis Using Graham's Net-Net Checklist 4:35 p.m. Jan. 2, 2015 - GuruFocus.com
Twitter 2015 Outlook: Promise Me You Will Change 2:56 p.m. Jan. 2, 2015 - Seeking Alpha
Twitter Tests Ad Space on Following List to Boost Revenues - Analyst Blog 1:50 p.m. Jan. 2, 2015 - Zacks.com
Wal-Mart's (WMT) Sam's Club Offers Membership Gift Cards - Analyst Blog 1:36 p.m. Jan. 2, 2015 - Zacks.com
10 Reasons Why Snapchat's $485.6 Million Fundraising Shows It's Worth $10 Billion 12:54 p.m. Jan. 2, 2015 - TheStreet.com
Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility 10:45 a.m. Jan. 2, 2015 - Seeking Alpha
Facebook Apologizes for Flaw in Year in Review Feature - Analyst Blog 9:10 a.m. Jan. 2, 2015 - Zacks.com
The 10 Best Stocks to Buy for 2015 9:10 a.m. Jan. 2, 2015 - InvestorPlace.com
Alibaba, Facebook Led Dual-Class 2014 Tech Stocks 8:41 a.m. Jan. 2, 2015 - Investors Business Daily
Profiting from the 'Rise of the Machines' 8:18 a.m. Jan. 2, 2015 - FOXBusiness
Dana Blankenhorn: Why Your Money Should Be On Tech In 2015 8:00 a.m. Jan. 2, 2015 - Seeking Alpha
Twitter News: TWTR Rolls Out New ‘While You Were Away’ Feature 6:58 a.m. Jan. 2, 2015 - InvestorPlace.com
Google Stock 2014 Timeline — Riding the GOOG Roller Coaster 6:40 a.m. Jan. 2, 2015 - InvestorPlace.com
Snapchat: Is it an IPO or Buyout? 5:52 a.m. Jan. 2, 2015 - InvestorPlace.com
20 Questions For 2015 1:18 a.m. Jan. 2, 2015 - Seeking Alpha
Unilever, P&G Tweak Formulas, Prices for Developing World 8:16 p.m. Jan. 1, 2015 - The Wall Street Journal Interactive Edition
New Year, New Job? Read This First 7:18 p.m. Jan. 1, 2015 - The Wall Street Journal Interactive Edition

Critical Alerts For Achillion Pharmaceuticals, AT&T, Peabody Energy, Gilead Sciences and Facebook Released By InvestorsObserver 9:31 a.m. Dec. 23, 2014 - PR Newswire - PRF
The Virtual Reality Storm Starting to Roll In 10:37 a.m. Dec. 19, 2014 - ACCESSWIRE
TrendPoint to Provide EnerSure(R) Enkapsis Across Facebook's Data Centers 8:02 a.m. Dec. 16, 2014 - Marketwired
Technical Coverage on Internet Software and Services Stocks - Facebook, Google, Bitauto Holdings, 58.com, and Autohome 9:05 a.m. Dec. 10, 2014 - PR Newswire - PRF
Critical Alerts For InvenSense, Francesca's Holdings Corporation, Vivint Solar Inc, Facebook and Discovery Communications Released By InvestorsObserver 9:31 a.m. Dec. 8, 2014 - PR Newswire - PRF
Facebook to Participate in the Credit Suisse Technology Conference 4:05 p.m. Nov. 25, 2014 - PR Newswire - PRF
Facebook Inc (FB: NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry 9:32 a.m. Nov. 20, 2014 - PR Newswire - PRF
Real Time Bidding Market (RTB) to Hit $42 Billion by 2018: 41% CAGR for 2014-2019 1:00 p.m. Nov. 16, 2014 - PR Newswire - PRF
Marriott, Coke and Others Utilizing Oculus Rift as Virtual Reality Could Transform Industries 9:40 a.m. Nov. 6, 2014 - ACCESSWIRE
Financial Results, Acquisition Agreements, Upcoming Events, Awards for Technology Initiatives - Research Reports on Facebook, Twitter, Sapient, Microsoft and Intel 8:55 a.m. Nov. 6, 2014 - PR Newswire - PRF
Critical Alerts For Invensense, AutoZone Inc., Ballard Power Systems, Facebook and Rite Aid Released By InvestorsObserver 9:31 a.m. Nov. 4, 2014 - PR Newswire - PRF
Scanning Internet Software and Services Equities - Facebook, Bankrate, LiveDeal, Google, and Bitauto Holdings 8:45 a.m. Oct. 30, 2014 - PR Newswire - PRF
Corporate Treasury Industry Insights at AFP 2014 Annual Conference 7:04 a.m. Oct. 30, 2014 - BusinessWire - BZX
Facebook Reports Third Quarter 2014 Results 4:01 p.m. Oct. 28, 2014 - PR Newswire - PRF
Innovative Technologies That Are Revolutionizing Spectator Sports 9:52 a.m. Oct. 28, 2014 - ACCESSWIRE
InvestorsObserver releases comments on Wal-Mart, Facebook, ConocoPhillips, AmerisourceBergen, and Clorox 9:31 a.m. Oct. 27, 2014 - PR Newswire - PRF
Firsthand Technology Value Fund Announces Distribution of $2.998210 Per Share 9:00 a.m. Oct. 20, 2014 - GlobeNewswire
Valuesetters Growing Business Along Same Principles As Netflix, Tangoe, And Skype 8:33 a.m. Oct. 20, 2014 - ACCESSWIRE
Firsthand Technology Value Fund Discloses Preliminary NAV of $29.70 Per Share as of September 30, 2014 9:00 a.m. Oct. 15, 2014 - GlobeNewswire
Critical Alerts For Ruby Tuesday, ExOne, Facebook, News Corp and Google Released By InvestorsObserver 9:31 a.m. Oct. 10, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...